Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
BioNTech SE(BNTX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BNTX
10/26/2026: BNTX (1-star) is currently NOT-A-BUY. Pass it for now.
BioNTech SE is a biotechnology company known for its pioneering role in mRNA technology, primarily validated by its COVID-19 vaccine development with Pfizer. The company possesses a strong cash position that supports a broad, high-growth-focused oncology pipeline. Its primary investment story centers on the potential success of individualized cancer vaccines and other immunotherapies. Key risks include heavy reliance on future clinical trial outcomes, intense competition in the oncology space, and declining pandemic-era revenues. This stock is best suited for growth-oriented investors who are comfortable with the inherent volatility of clinical-stage biotech and are monitoring progress in the company's transition toward cancer therapeutics.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is aggressively investing in R&D to commercialize a pipeline of novel cancer therapeutics. |
| Momentum investor | Mixed fit | Momentum depends on clinical trial data readouts and potential regulatory breakthroughs. |
| Value investor | Weak fit | Current valuation is highly dependent on future pipeline success rather than current cash-flow-based metrics. |
| Dividend investor | Weak fit | The company does not pay dividends, focusing exclusively on capital appreciation through R&D. |
| Low-risk investor | Weak fit | The biotechnology sector and the company's dependency on clinical outcomes create high investment risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Stock performance is sensitive to clinical trial results and pandemic-related revenue fluctuations. |
| Valuation risk | Medium / high | Future growth expectations are baked into the stock price, leaving little room for negative clinical surprises. |
| Competition risk (Biotech & Pharma) | High | Intense competition in the oncology space from both established pharma and emerging biotech firms could erode potential market share. |
| Business quality | Medium | While the platform is robust, transitioning from a single-product success to a diversified pipeline remains a key execution challenge. |
| Dividend income | Low / none | Investors should not expect income, as capital is fully allocated to growth. |
| Execution risk | Medium / high | The complexity of developing personalized cancer vaccines involves significant scientific and regulatory hurdles. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -43.48% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/26/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 22.13B USD | Price to earnings Ratio - | 1Y Target Price 116.7 |
Price to earnings Ratio - | 1Y Target Price 116.7 | ||
Volume (30-day avg) 1.0M shares | Beta 1.25 | 52 Weeks Range 79.52 - 124.00 | Updated Date 10/25/2026 |
52 Weeks Range 79.52 - 124.00 | Updated Date 10/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.83 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Infectious Disease Vaccines | Global sales of Comirnaty and associated booster formulations. | The primary historical revenue driver, though sales are normalizing as pandemic demand wanes. |
| Oncology Research & Development | Collaborations and potential future therapeutic sales. | This represents the long-term investment thesis, aiming to move beyond pandemic-era vaccines. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-03 | When Before Market | Estimate 0.85 | Actual - |
Profitability
Profit Margin -63.64% | Operating Margin (TTM) -806.63% |
Management Effectiveness
Return on Assets (TTM) -5.41% | Return on Equity (TTM) -9.3% |
Valuation
Trailing PE - | Forward PE 7.04 | Enterprise Value 8.97B | Price to Sales(TTM) 8.35 |
Enterprise Value 8.97B | Price to Sales(TTM) 8.35 | ||
Enterprise Value to Revenue 2.66 | Enterprise Value to EBITDA 110.81 | Shares Outstanding 251.20M | Shares Floating 109.28M |
Shares Outstanding 251.20M | Shares Floating 109.28M | ||
Percent Insiders 57.19 | Percent Institutions 20.59 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.